NeoGenomics (NASDAQ: NEO) reported Q1 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $187 million versus the consensus estimate of $184.53 million.

GUIDANCE:

NeoGenomics sees FY2026 revenue of $797-803 million, versus the consensus of $796.6 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.